Neuroreplacement strategies by mesenchymal stem cell

描述（由申请人提供）：

DESCRIPTION (provided by applicant): In our previous study, human neural stem cells (HNSCs), proliferated in vitro for more than a year and transplanted into 24-month-old rat brains, migrated and differentiated into neural cells, and significantly improved the cognitive functions of these animals. Although HNSCs are a valuable source of transplantable material as an alternative to fetal neural tissue, the ideal replacement therapies would be the autologous transplantation. Since we have succeeded in producing neural cells from human mesenchymal stem cells (HMeSCs}, we propose the use of HMeSC for neuroreplacement therapies. Our long-range goal is to identify the regulation of the mechanisms of stem cell lineage and to establish neuroreplacement therapy using HMeSCs isolated from individual patients. The central hypothesis of this application is that HMeSCs treated with bromodeoxyuridin (BrdU) produce neural cells that are functionally similar to HNSC-derived cells. The objectives of this project are to find clues for the regulation of mechanisms for stem cell lineage, and to collect basic data for optimal neuroreplacement therapies using HMeSCs. Aim 1. Investigation of the effects of BrdU on neural differentiation of MeSCs. Aim 2. Time-course assessment of HMeSC migration and differentiation after transplantation into the adult brain. Aim 3. To investigate whether MeSC transplantation improves the cognitive functions of aged memory-impaired rats. Aim 4. To investigate whether there is a specific temporal window for efficient neuroreplacement by MeSCs in an Alzheimer's disease lesion model. The proposed research is innovative, because it focuses on the ability of a biological function; i.e., the use of BrdU, to change the lineage of MeSCs, which may facilitate autologous transplantation in neuroreplacement strategies. This proposal is expected to have the following outcomes: (1) a demonstration that BrdU treatment alters HMeSC lineage to produce neural cells in vitro by DNA methylation modification; (2) a demonstration that BrdU-treated HMeSCs differentiate and migrate into their proper position in the adult brain after i.c.v, transplantation; (3) a recovery of cognitive function by HMeSC transplantation in an aged animal model; and (4) a replacement of neurons in an Alzheimer's disease lesion model. The proposed research is expected to provide fundamental data to develop clinical applications for MeSCs transplantation in patients with neurodegenerative diseases through autologus transplantation. Thus, the proposed studies are expected to make a breakthrough in therapeutic strategies.